

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumension Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

## **CHANGE OF NON-EXECUTIVE DIRECTOR**

### **RESIGNATION OF A NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Wei LI (“**Dr. Li**”), after more than six years of service, has tendered his resignation from the position as a non-executive Director with immediate effect due to his desire to devote more time to his other engagements.

Dr. Li has confirmed that he has no disagreement with the Board and there is no other matter in connection with his resignation as a non-executive Director that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Dr. Li for his valuable contributions to the Company during his tenure of office.

### **APPOINTMENT OF A NON-EXECUTIVE DIRECTOR**

The Board further announces that Dr. Qin XIE (謝沁) (“**Dr. Xie**”) has been appointed as a non-executive Director with effect from January 16, 2025. The biographical details of Dr. Xie are as follows:

Dr. Qin XIE (謝沁), aged 44, has more than 10 years of extensive experience in pharmaceuticals-related industry. Since September 2017, Dr. Xie has been working in Frontline BioVentures (Shanghai) Limited (崇凱創業投資諮詢(上海)有限公司) (the management company of Suzhou Frontline BioVentures Venture Capital Fund II L.P. (蘇州通和二期創業投資合夥企業(有限合夥)) and Suzhou 6 Dimensions Venture Capital Partnership L.P. (蘇州通和毓承投資合夥企業(有限合夥)), each a controlling shareholder of the Company), where she currently serves as a managing partner, primarily responsible for overseeing the overall strategic development. Dr. Xie was also our advisor from February 2018 to December 2020. From January 2016 to August 2017, she worked at 6 Dimensions Venture Consultant (Shanghai) Co., Ltd. (毓承投資諮詢(上海)有限公司). From September 2013 to December 2015, she had served as a business development manager in Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. (輝正(上海)醫藥科技有限公司),

a subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. (浙江海正藥業股份有限公司), which is a pharmaceutical company listed on the Shanghai Stock Exchange (stock code: 600267). From November 2010 to December 2012, Dr. Xie served as a senior investment manager in Shanghai Pharmaceuticals Holding Co. Ltd. (上海醫藥集團股份有限公司), a company primarily engaged in the pharmaceutical industry with its shares listed on both the Shanghai Stock Exchange (stock code: 601607) and the Stock Exchange (stock code: 2607).

Dr. Xie served as a director from August 2019 to November 2022 and was redesignated as a non-executive director in November 2022 of Cutia Therapeutics (科笛集團), a biotech company whose shares are listed on the Stock Exchange (stock code: 2487).

Dr. Xie obtained her bachelor's degree in clinical medicine from the Xi'an Jiaotong University (西安交通大學) in the PRC in July 2003. She then received her master's degree in pharmacology and doctorate degree in pharmacology from University of Oxford in the United Kingdom in September 2004 and April 2011, respectively.

The Board considered and accepted the recommendation from the nomination committee of the Company to appoint Dr. Xie as a non-executive Director, after reviewing her academic and professional qualifications and work experience, among others.

Dr. Xie enters into a service agreement with the Company with an initial term of three years commencing from January 16, 2025, which is subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company, or vacation from office pursuant to any applicable laws from time to time. Dr. Xie shall hold office as a non-executive Director only until the next annual general meeting of the Company, and shall be eligible for re-election in accordance with the articles of association of the Company. Dr. Xie will not receive any director's fee for her term of appointment.

Save as disclosed above, Dr. Xie does not hold any positions in the Company or any of its subsidiaries and does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company, nor did she hold any directorships in any listed companies in the past three years prior to the date of this announcement. As of the date of this announcement, Dr. Xie did not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Xie has not been subject to any penalty or punishment imposed by any relevant authorities or stock exchanges. Save as disclosed above, the Board is not aware of other information on the appointment of Dr. Xie which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") or other matters that need to be brought to the attention of the Shareholders.

Dr. Xie has obtained the legal advice referred to under Rule 3.09D of the Listing Rules prior to her appointment, and confirmed that she understood her obligations as a Director under the Listing Rules.

The Board would like to take this opportunity to extend its warmest welcome to Dr. Xie on her new appointment.

## COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES

Reference is made to the announcement of the Company dated October 21, 2024 with respect to the resignation of a non-executive director of the Company. Following the appointment of Dr. Xie as a non-executive Director, the Company has achieved the gender diversity for members of the Board and is in full compliance with the requirements under Rule 13.92 of the Listing Rules.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, January 16, 2025

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.*